Pharmocann Global Ltd

TASE:PMCN-M Rapporto sulle azioni

Cap. di mercato: ₪3.8m

Pharmocann Global Performance dei guadagni passati

Il passato criteri di controllo 0/6

Pharmocann Global has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 9.1% per year.

Informazioni chiave

15.6%

Tasso di crescita degli utili

40.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore35.1%
Tasso di crescita dei ricavi-9.1%
Rendimento del capitale proprio-4,587.4%
Margine netto-76.1%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence

Mar 30
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence

Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?

Feb 04
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?

Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Dec 31
Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come

Nov 26
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come

Ripartizione dei ricavi e delle spese

Come Pharmocann Global guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

TASE:PMCN-M Ricavi, spese e utili (ILS Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2413-1080
31 Mar 2414-1080
31 Dec 2314-1080
30 Sep 2311-1260
30 Jun 2312-1871
31 Mar 2317-24101
31 Dec 2223-25131
30 Sep 2224-23121
30 Jun 2225-20131
31 Mar 2228-16151
31 Dec 2129-19151
30 Sep 2131-14151
30 Jun 2132-7151
31 Mar 21312131
31 Dec 20284131
30 Sep 20266111
30 Jun 20265101
31 Mar 2021-2591
31 Dec 1921-4661
30 Sep 1918-4660
30 Jun 1917-4640
31 Mar 1916-2040
31 Dec 1815630
31 Dec 1712230
31 Dec 169120

Guadagni di qualità: PMCN-M is currently unprofitable.

Margine di profitto in crescita: PMCN-M is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.

Accelerare la crescita: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).


Rendimento del capitale proprio

ROE elevato: PMCN-M has a negative Return on Equity (-4587.44%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate